Renaissance Technologies LLC grew its position in shares of Achillion Pharmaceuticals (NASDAQ:ACHN) by 128.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,182,467 shares of the biopharmaceutical company’s stock after acquiring an additional 1,228,492 shares during the period. Renaissance Technologies LLC owned about 1.58% of Achillion Pharmaceuticals worth $6,286,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of ACHN. Teacher Retirement System of Texas purchased a new position in shares of Achillion Pharmaceuticals during the fourth quarter valued at about $109,000. SG Americas Securities LLC grew its holdings in Achillion Pharmaceuticals by 59.8% in the third quarter. SG Americas Securities LLC now owns 42,229 shares of the biopharmaceutical company’s stock worth $190,000 after purchasing an additional 15,800 shares during the period. Bourgeon Capital Management LLC grew its holdings in Achillion Pharmaceuticals by 64.4% in the fourth quarter. Bourgeon Capital Management LLC now owns 48,504 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 19,004 shares during the period. Virtus Fund Advisers LLC purchased a new stake in Achillion Pharmaceuticals in the fourth quarter worth about $349,000. Finally, Matisse Capital grew its holdings in Achillion Pharmaceuticals by 15.8% in the fourth quarter. Matisse Capital now owns 135,445 shares of the biopharmaceutical company’s stock worth $390,000 after purchasing an additional 18,500 shares during the period. 82.04% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently commented on the stock. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 6th. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, February 27th. Finally, B. Riley began coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, February 8th. They set a “neutral” rating and a $3.50 price objective on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. Achillion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $4.89.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). During the same quarter in the prior year, the firm earned ($0.03) EPS. analysts forecast that Achillion Pharmaceuticals will post -0.55 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://stocknewstimes.com/2018/04/21/renaissance-technologies-llc-has-6-29-million-position-in-achillion-pharmaceuticals-achn.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.